Difference between revisions of "Part:BBa K5351005"
 
(2 intermediate revisions by one other user not shown)
Line 31: Line 31:
 
     <!-- Figure 1 -->
 
     <!-- Figure 1 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/1.png" width="50%" alt="Figure 1. Gene map of PsXI">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/1.png" width="60%" alt="Figure 1. Gene map of PsXI">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 1. Gene map of PsXI</caption>
 
             <caption>Figure 1. Gene map of PsXI</caption>
Line 46: Line 46:
 
     <!-- Figure 2 -->
 
     <!-- Figure 2 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/2.jpg" width="50%" alt="Figure 2. Amplification result of TEF1 pro, PsXI, and ADH1 ter">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/2.jpg" width="40%" alt="Figure 2. Amplification result of TEF1 pro, PsXI, and ADH1 ter">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 2. Amplification result of TEF1 pro, PsXI, and ADH1 ter</caption>
 
             <caption>Figure 2. Amplification result of TEF1 pro, PsXI, and ADH1 ter</caption>
Line 56: Line 56:
 
     <!-- Figure 3 -->
 
     <!-- Figure 3 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/3.jpg" width="50%" alt="Figure 3. Overlap PCR result of TEF1-PsXI-ADH1">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/3.jpg" width="40%" alt="Figure 3. Overlap PCR result of TEF1-PsXI-ADH1">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 3. Overlap PCR result of TEF1-PsXI-ADH1</caption>
 
             <caption>Figure 3. Overlap PCR result of TEF1-PsXI-ADH1</caption>
Line 66: Line 66:
 
     <!-- Figure 4 -->
 
     <!-- Figure 4 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/4.jpg" width="50%" alt="Figure 4. Validation of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/4.jpg" width="40%" alt="Figure 4. Validation of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 4. Validation of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1</caption>
 
             <caption>Figure 4. Validation of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1</caption>
Line 80: Line 80:
 
     <!-- Figure 5 -->
 
     <!-- Figure 5 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/5.png" width="50%" alt="Figure 5. The Monoclonal antibody validation and sequencing of X-3-XI (DH5α)">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/5.png" width="40%" alt="Figure 5. The Monoclonal antibody validation and sequencing of X-3-XI (DH5α)">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 5. The Monoclonal antibody validation and sequencing of X-3-XI (DH5α)  
 
             <caption>Figure 5. The Monoclonal antibody validation and sequencing of X-3-XI (DH5α)  
Line 93: Line 93:
 
     <!-- Figure 6 -->
 
     <!-- Figure 6 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/6.jpg" width="50%" alt="Figure 6. Validation result of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/6.jpg" width="40%" alt="Figure 6. Validation result of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 6. Validation result of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1</caption>
 
             <caption>Figure 6. Validation result of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1</caption>
Line 107: Line 107:
 
     <!-- Figure 7 -->
 
     <!-- Figure 7 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/7.png" width="50%" alt="Figure 7. The Monoclonal antibody validation and sequencing of XI-2-XI (DH5α)">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/7.png" width="40%" alt="Figure 7. The Monoclonal antibody validation and sequencing of XI-2-XI (DH5α)">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 7. The Monoclonal antibody validation and sequencing of XI-2-XI (DH5α)  
 
             <caption>Figure 7. The Monoclonal antibody validation and sequencing of XI-2-XI (DH5α)  
Line 116: Line 116:
 
</body>
 
</body>
 
</html>
 
</html>
 +
 +
<html lang="en">
 +
<head>
 +
    <meta charset="UTF-8">
 +
    <meta charset="UTF-8">
 +
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
 +
    <title>BBa_K5351005 Documentation</title>
 +
</head>
 +
<body>
 +
 +
    <!-- Previous Sections Here -->
 +
 
     <!-- 3. X-3-2XI Section -->
 
     <!-- 3. X-3-2XI Section -->
 
     <h3>3. X-3-2XI</h3>
 
     <h3>3. X-3-2XI</h3>
Line 122: Line 134:
 
     <!-- Figure 8 -->
 
     <!-- Figure 8 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/8.jpg" width="50%" alt="Figure 8. Amplification result of GAP pro, PsXI, and CYC1 ter">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/8.jpg" width="40%" alt="Figure 8. Amplification result of GAP pro, PsXI, and CYC1 ter">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 8. Amplification result of GAP pro, PsXI, and CYC1 ter</caption>
 
             <caption>Figure 8. Amplification result of GAP pro, PsXI, and CYC1 ter</caption>
Line 132: Line 144:
 
     <!-- Figure 9 -->
 
     <!-- Figure 9 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/9.jpg" width="50%" alt="Figure 9. Overlap PCR result of GAP-PsXI-CYC1">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/9.jpg" width="40%" alt="Figure 9. Overlap PCR result of GAP-PsXI-CYC1">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 9. Overlap PCR result of GAP-PsXI-CYC1</caption>
 
             <caption>Figure 9. Overlap PCR result of GAP-PsXI-CYC1</caption>
Line 142: Line 154:
 
     <!-- Figure 10 -->
 
     <!-- Figure 10 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/10.jpg" width="50%" alt="Figure 10. Validation of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/10.jpg" width="40%" alt="Figure 10. Validation of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 10. Validation of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1</caption>
 
             <caption>Figure 10. Validation of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1</caption>
Line 156: Line 168:
 
     <!-- Figure 11 -->
 
     <!-- Figure 11 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/11.png" width="50%" alt="Figure 11. The Monoclonal antibody validation and sequencing of X-3-2XI (DH5α)">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/11.png" width="40%" alt="Figure 11. The Monoclonal antibody validation and sequencing of X-3-2XI (DH5α)">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 11. The Monoclonal antibody validation and sequencing of X-3-2XI (DH5α)  
 
             <caption>Figure 11. The Monoclonal antibody validation and sequencing of X-3-2XI (DH5α)  
Line 169: Line 181:
 
     <!-- Figure 12 -->
 
     <!-- Figure 12 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/12.jpg" width="50%" alt="Figure 12. Validation result of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/12.jpg" width="40%" alt="Figure 12. Validation result of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 12. Validation result of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1</caption>
 
             <caption>Figure 12. Validation result of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1</caption>
Line 183: Line 195:
 
     <!-- Figure 13 -->
 
     <!-- Figure 13 -->
 
     <div style="text-align:center;">
 
     <div style="text-align:center;">
−
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/13.png" width="50%" alt="Figure 13. The Monoclonal antibody validation and sequencing of XI-2-2XI (DH5α)">
+
         <img src="https://static.igem.wiki/teams/5351/bba-k5351005/13.png" width="40%" alt="Figure 13. The Monoclonal antibody validation and sequencing of XI-2-2XI (DH5α)">
 
         <div style="text-align:center;">
 
         <div style="text-align:center;">
 
             <caption>Figure 13. The Monoclonal antibody validation and sequencing of XI-2-2XI (DH5α)  
 
             <caption>Figure 13. The Monoclonal antibody validation and sequencing of XI-2-2XI (DH5α)  
Line 192: Line 204:
 
</body>
 
</body>
 
</html>
 
</html>
−
html
 
−
 
−
What's included:
 
−
 
−
3. X-3-2XI: Construction and validation of the X-3-2XI plasmid containing two copies of the XI gene. This section includes:
 
−
Figure 8: PCR validation of GAP promoter, PsXI coding gene, and CYC1 terminator.
 
−
Figure 9: Overlap PCR result of GAP-PsXI-CYC1.
 
−
Figure 10: Validation of the backbone X-3-XI and target gene GAP-PsXI-CYC1.
 
−
Figure 11: Colony PCR and sequencing validation of X-3-2XI.
 
−
4. XI-2-2XI: Construction and validation of the XI-2-2XI plasmid, with:
 
−
Figure 12: Validation result of XI-2-XI and GAP-PsXI-CYC1.
 
−
Figure 13: Colony PCR and sequencing validation of XI-2-2XI.
 
−
 
−
This completes the full document, with all figures and their descriptions included for the X-3-2XI and XI-2-2XI plasmid constructions. Let me know if further adjustments are needed!
 

Latest revision as of 06:35, 29 September 2024

PsXI



Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal AgeI site found at 910
  • 1000
    COMPATIBLE WITH RFC[1000]

BBa_K5351005 Documentation

Origin

Saccharomyces cerevisiae; synthesized

Properties

Xylose isomerase (XI) is an enzyme responsible for catalyzing the isomerization of xylose to xylulose, an essential step in the metabolism of xylose.

Usage and Biology

Xylose isomerase (XI) is an enzyme responsible for catalyzing the isomerization of xylose to xylulose, an essential step in the metabolism of xylose. This enzyme is crucial in microbial strains engineered for xylose utilization, as it enables the conversion of xylose into a form that can enter the pentose phosphate pathway for energy production. XI plays a crucial role in enhancing the efficiency of xylose utilization in various biotechnological applications, such as biofuel production and metabolic engineering of microorganisms for the conversion of lignocellulosic biomass into valuable products.

Figure 1. Gene map of PsXI
Figure 1. Gene map of PsXI

Experimental Approach

1. X-3-XI

We constructed a plasmid X-3-XI containing a single copy of the XI gene. Figure 2 shows the PCR validation results for the promoter TEF1, the coding gene PsXI, and the terminator ADH1, with band sizes matching the expected lengths of 430 bp, 1354 bp, and 214 bp, respectively, indicating successful amplification.

Figure 2. Amplification result of TEF1 pro, PsXI, and ADH1 ter
Figure 2. Amplification result of TEF1 pro, PsXI, and ADH1 ter

Overlap PCR was performed on these fragments. Figure 3 shows the results of the overlap PCR, with a band size consistent with the expected length of 1920 bp, indicating successful synthesis of the target gene.

Figure 3. Overlap PCR result of TEF1-PsXI-ADH1
Figure 3. Overlap PCR result of TEF1-PsXI-ADH1

We amplified and validated the backbone X-3 and the target gene TEF1-PsXI-ADH1. The results in Figure 4 showed matching band sizes, indicating successful amplification.

Figure 4. Validation of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1
Figure 4. Validation of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1

We ligated the X-3 backbone and the target gene TEF1-PsXI-ADH1 and transformed it into competent E.coli DH5α. Figure 5a shows the results after culturing E. coli, where single colonies can be observed.

We performed colony PCR to validate the cultured colonies, and Figure 5b displays the results of the colony PCR, showing bands of approximately 2065 bp, consistent with the expected fragment size, validating our successful transformation and plasmid construction.

The colonies were also sent for sequencing. According to the results shown in Figure 5c, the TEF1-PsXI-ADH1 gene was successfully ligated to the backbone without any apparent mutations, confirming the successful construction of the X-3-XI plasmid.

Figure 5. The Monoclonal antibody validation and sequencing of X-3-XI (DH5α)
Figure 5. The Monoclonal antibody validation and sequencing of X-3-XI (DH5α)
(a: X-3-XI colonies; b: Gel electrophoresis validation of colony PCR of X-3-2XI colonies; c: Sequencing result of X-3-2XI)

2. XI-2-XI

We constructed a plasmid XI-2-XI containing a single copy of the XI gene. We amplified and validated the backbone XI-2 and the target gene TEF1-PsXI-ADH1. The results in Figure 6 showed matching band sizes, indicating successful amplification.

Figure 6. Validation result of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1
Figure 6. Validation result of linear pX-3, linear pXI-2, and TEF1-PsXI-ADH1

We ligated the XI-2 backbone and the target gene TEF1-PsXI-ADH1 and transformed it into competent E.coli DH5α. Figure 7a shows the results after culturing E. coli, where single colonies can be observed.

We performed colony PCR to validate the cultured colonies, and Figure 7b displays the results of the colony PCR, showing bands of approximately 2065 bp, consistent with the expected fragment size, validating our successful transformation and plasmid construction.

The colonies were also sent for sequencing. According to the results shown in Figure 7c, the TEF1-PsXI-ADH1 gene was successfully ligated to the backbone without any apparent mutations, confirming the successful construction of the XI-2-XI plasmid.

Figure 7. The Monoclonal antibody validation and sequencing of XI-2-XI (DH5α)
Figure 7. The Monoclonal antibody validation and sequencing of XI-2-XI (DH5α)
(a: XI-2-XI colonies; b: Validation of colony PCR of XI-2-PsXI; c: Sequencing result of XI-2-XI)

BBa_K5351005 Documentation

3. X-3-2XI

We constructed a plasmid X-3-2XI containing two copies of the XI genes. Figure 8 shows the PCR validation results for the promoter GAP, the coding gene PsXI, and the terminator CYC1, with band sizes matching the expected lengths of 693 bp, 1350 bp, and 275 bp, respectively, indicating successful amplification.

Figure 8. Amplification result of GAP pro, PsXI, and CYC1 ter
Figure 8. Amplification result of GAP pro, PsXI, and CYC1 ter

Overlap PCR was performed on these fragments, and Figure 9 shows the results of the overlap PCR, with a band size consistent with the expected length of 2245 bp, indicating successful synthesis of the target gene.

Figure 9. Overlap PCR result of GAP-PsXI-CYC1
Figure 9. Overlap PCR result of GAP-PsXI-CYC1

We amplified and validated the backbone X-3-XI and the target gene GAP-PsXI-CYC1. The results in Figure 10 showed matching band sizes, indicating successful amplification.

Figure 10. Validation of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1
Figure 10. Validation of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1

We ligated the X-3-XI backbone and the target gene GAP-PsXI-CYC1 and transformed it into competent E.coli DH5α. Figure 11a shows the results after culturing E. coli, where single colonies can be observed.

We performed colony PCR to validate the cultured colonies, and Figure 11b displays the results of the colony PCR, showing bands of approximately 904 bp, consistent with the expected fragment size, validating our successful transformation and plasmid construction.

The colonies were also sent for sequencing. According to the results shown in Figure 11c, the GAP-PsXI-CYC1 gene was successfully ligated to the backbone without any apparent mutations, confirming the successful construction of the X-3-2XI plasmid.

Figure 11. The Monoclonal antibody validation and sequencing of X-3-2XI (DH5α)
Figure 11. The Monoclonal antibody validation and sequencing of X-3-2XI (DH5α)
(a: X-3-2XI colonies; b: Validation of colony PCR of X-3-2XI; c: Sequencing result of X-3-2XI)

4. XI-2-2XI

We constructed a plasmid XI-2-2XI containing two copies of the XI genes. We amplified and validated the backbone XI-2-XI and the target gene GAP-PsXI-CYC1. The results in Figure 12 showed matching band sizes, indicating successful amplification.

Figure 12. Validation result of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1
Figure 12. Validation result of X-3-XI, XI-2-XI, and GAP-PsXI-CYC1

We ligated the XI-2-XI backbone and the target gene GAP-PsXI-CYC1 and transformed it into competent E.coli DH5α. Figure 13a shows the results after culturing E. coli, where single colonies can be observed.

We performed colony PCR to validate the cultured colonies, and Figure 13b displays the results of the colony PCR, showing bands of approximately 904 bp, consistent with the expected fragment size, validating our successful transformation and plasmid construction.

The colonies were also sent for sequencing. According to the results shown in Figure 13c, the GAP-PsXI-CYC1 gene was successfully ligated to the backbone without any apparent mutations, confirming the successful construction of the XI-2-2XI plasmid.

Figure 13. The Monoclonal antibody validation and sequencing of XI-2-2XI (DH5α)
Figure 13. The Monoclonal antibody validation and sequencing of XI-2-2XI (DH5α)
(a: XI-2-2XI colonies; b: Validation of colony PCR of XI-2-2XI; c: Sequencing result of XI-2-2XI)